Clinical and Biological Characteristics According to the Burden of JAK2V617F Mutated Allele in BCR-ABL Negative MPNs
Lurdes Zamora(Universitat Autònoma de Barcelona), Fuensanta Millá, Imma Portal(Maresme Health Consortium), David Gallardo(Instituto Nacional de Cancerología), Sílvia Marcé(Josep Carreras Leukaemia Research Institute), Lluís Rodríguez(Hospital de l'Esperança), Natividad Lopez(Hospital Municipal de Badalona), Isabel Granada(Josep Carreras Leukaemia Research Institute), Esther Alonso(Bellvitge University Hospital), Joan Buch(Clínica Girona), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Luz San Miguel(Universitat Autònoma de Barcelona), Esther Plensa(Hospital de Mataró), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Diana Domínguez(Institute for Research in Biomedicine), Josep‐María Ribera(Universitat Autònoma de Barcelona), Marta Cabezón(Universitat Autònoma de Barcelona), Neus Ruiz‐Xivillé(Josep Carreras Leukaemia Research Institute), Olga García(Institut Català d'Oncologia), C. Mauleón Fernández(Hospital Universitari de Girona Doctor Josep Trueta), Concha Boqué(Institut Català d'Oncologia), Marisol Xandri(Fundación Josep Carreras Contra la Leucemia), Dolors Vela(Hospital General de Granollers), Evarist Feliú(Universitat Autònoma de Barcelona)
Cited by 0
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|457
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
|Blood|2016|329
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309